Table 1 Characteristics of patients upon the diagnosis of autoimmune hepatitis in 2018 and 2015.
From: Increasing incidence of acute autoimmune hepatitis: a nationwide survey in Japan
2018 | 2015 | 2015 vs. 2018 | |||
|---|---|---|---|---|---|
Variable | Value | Available no. of patients | Value | Available no. of patients | P |
Age (years) | 63 (52–70) | 783 | 62 (53–70) | 1,386 | 0.592 |
Female (%) | 84.0 (669) | 796 | 88.1 (1,238) | 1,405 | 0.009 |
AST (U/L) | 216 (86–512) | 788 | 187 (81–507) | 1,407 | 0.020 |
ALT (U/L) | 255 (91–628) | 788 | 214 (84–543) | 1,408 | 0.011 |
ALP (U/L) | 430 (322–614) | 781 | 424 (306–587) | 1,393 | 0.304 |
\(\gamma\)-GTP (U/L) | 158 (86–289) | 786 | 146 (80–260) | 1,395 | 0.041 |
Total bilirubin (mg/dL) | 1.2 (0.8–4.0) | 786 | 1.1 (0.7–2.8) | 1,394 | 0.024 |
Prothrombin time (INR) | 1.09 (1.02–1.21) | 719 | – | – | – |
Prothrombin time (%) | 84 (69–96) | 730 | – | – | – |
IgG (mg/dL) | 2090 (1,670–2,697) | 769 | 2,251 (1835–2,885) | 1,378 | < 0.001 |
ANA titer | 160 (40–640) | 764 | 160 (80–640) | 1,362 | < 0.001 |
ANA positivity | 86.2% (674) | 782 | 93.8% (1,312) | 1,398 | < 0.001 |
ASMA positivity | 37.4% (96) | 257 | 42.4% (191) | 450 | 0.213 |
AMA positivity | 14.8% (107) | 725 | 15.9% (107) | 675 | 0.622 |
LKM1 antibody positivity | 6.0% (13) | 218 | 13.5% (56) | 414 | 0.006 |
Revised IAIHSG score | 15 (13–18) | 731 | 15 (13–18) | 1,409 | 0.412 |
Simplified score | 6 (5–7) | 693 | 6 (5–7) | 1,410 | 0.051 |
Hepatitis B surface antigen positivity | 0.6% (4) | 680 | 0.3% (4) | 1,402 | 0.503 |
Hepatitis B core antibody positivity | 17.4% (105) | 605 | 21.6% (175) | 809 | 0.054 |
Hepatitis C antibody positivity | 1.4% (11) | 776 | 3.2% (45) | 1,391 | 0.016 |
Hepatitis C RNA positivity | 1.8% (3) | 164 | 8.1% (24) | 296 | 0.011 |
HLA-DR4 positivity | 63.5% (80) | 126 | 68.9% (182) | 264 | 0.339 |
HLA-DR2 positivity | 6.6% (8) | 122 | 9.6% (24) | 251 | 0.438 |
Histologic diagnosis | |||||
Acute hepatitis | 21.7% (157) | 723 | 11.0% (135) | 1,225 | < 0.001 |
Chronic hepatitis | 70.0% (506) | 723 | 81.9% (1,003) | 1,225 | < 0.001 |
Liver cirrhosis | 8.3% (60) | 723 | 7.1% (87) | 1,225 | 0.380 |
Basic histology | |||||
Interface hepatitis 0/1/2 | 31/107/559 | 697 | 35/270/901 | 1,206 | 0.014 |
Portal inflammation 0/1/2 | 25/130/535 | 690 | 41/273/867 | 1,181 | 0.059 |
Plasma cell infiltration 0/1/2 | 69/178/436 | 683 | 106/437/584 | 1,127 | < 0.001 |
Lobular necrosis/inflammation 0/1/2 | 109/187/383 | 679 | 97/410/617 | 1,124 | 0.431 |
Fibrosis 0/1/2/3/4 | 91/234/177/104/45 | 651 | 105/387/352/207/82 | 1,133 | 0.005 |
Frequency of bile duct injury | 22.4% (147) | 656 | 23.8% (251) | 1,055 | 0.549 |
Frequency of hepatocyte rosette formation | 35.9% (220) | 613 | 43.8% (418) | 955 | 0.002 |
Frequency of centrilobular necrosis | 36.2% (204) | 564 | 33.0% (251) | 761 | 0.250 |
Frequency of emperipolesis | 28.1% (112) | 398 | 14.5% (68) | 469 | < 0.001 |
Frequency of fatty change | 18.1% (125) | 691 | 17.8% (212) | 1,192 | 0.917 |
